Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was upgraded by stock analysts at Wedbush from a “neutral” rating to an “outperform” rating in a research note issued on Thursday.

Several other analysts also recently weighed in on RARE. HC Wainwright reiterated a “neutral” rating and set a $75.00 target price (up from $72.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 8th. Jefferies Group LLC reiterated a “hold” rating and set a $68.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, July 14th. Evercore ISI assumed coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, August 16th. They set an “in-line” rating and a $63.00 target price for the company. Canaccord Genuity reiterated a “buy” rating and set a $83.00 target price (down from $98.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 22nd. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $85.00 target price (down from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical presently has an average rating of “Hold” and an average price target of $74.00.

Shares of Ultragenyx Pharmaceutical (NASDAQ RARE) opened at 49.79 on Thursday. The stock has a 50 day moving average of $58.78 and a 200-day moving average of $64.17. The stock’s market capitalization is $2.11 billion. Ultragenyx Pharmaceutical has a 52-week low of $49.56 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same period in the prior year, the company earned ($1.46) EPS. Analysts predict that Ultragenyx Pharmaceutical will post ($7.21) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Upgraded to Outperform by Wedbush” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/14/ultragenyx-pharmaceutical-inc-rare-upgraded-to-outperform-by-wedbush.html.

In other news, CEO Emil D. Kakkis bought 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, August 28th. The stock was acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the acquisition, the chief executive officer now owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 9.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in RARE. Sei Investments Co. bought a new position in Ultragenyx Pharmaceutical in the second quarter worth about $125,000. Pacer Advisors Inc. raised its holdings in Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 560 shares in the last quarter. Strs Ohio raised its holdings in Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 300 shares in the last quarter. Tocqueville Asset Management L.P. raised its holdings in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares in the last quarter. Finally, Kazazian Asset Management LLC bought a new position in Ultragenyx Pharmaceutical in the second quarter worth about $213,000. Institutional investors and hedge funds own 96.18% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.